Compare ALDX & DAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALDX | DAVA |
|---|---|---|
| Founded | 2004 | 2000 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.7M | 365.7M |
| IPO Year | 2014 | 2015 |
| Metric | ALDX | DAVA |
|---|---|---|
| Price | $5.00 | $5.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $9.50 | ★ $14.57 |
| AVG Volume (30 Days) | ★ 902.4K | 469.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $123.43 | $4.80 |
| P/E Ratio | ★ N/A | $20.02 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.18 | $4.38 |
| 52 Week High | $7.14 | $22.94 |
| Indicator | ALDX | DAVA |
|---|---|---|
| Relative Strength Index (RSI) | 47.77 | 45.44 |
| Support Level | $4.74 | $4.85 |
| Resistance Level | $5.70 | $7.04 |
| Average True Range (ATR) | 0.37 | 0.36 |
| MACD | -0.04 | 0.11 |
| Stochastic Oscillator | 48.36 | 54.01 |
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.